Anti-IL-11 antibody is effective in preventing bleomycin-induced lung fibrosis in mice and antibodies to IL-11 are now in development for treating IPF and other fibrotic diseases (Ng et al, 2019). Here, IL11 is linked to idiopathic pulmonary fibrosis.